News

Stocktwits on MSN5d
Regeneron To Buy Licensing Rights For China-Developed Investigational Obesity Drug For $2B: Retail Sees Stock Hitting $500
Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...
Pharmaceutical Technology on MSN4d
Regeneron to acquire rights for Hansoh’s HS-20094 therapy
Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094. The agreement will involve the clinical development and ...
PharmExec5d
Roundup: Pharma Giants Expand Strategic Pipelines Through Targeted M&A and Partnerships
Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...
Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target
Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...
Regeneron Signs Licensing Agreement for Chinese Weight Loss Drug
Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China.